EGFR and non-small cell lung carcinoma: A 42% median baseline incidence of bone metastases in patients with NSCLC and an EGFR mutation was reported, which is slightly lower compared to the 54% baseline incidence reported in the Dutch nationwide database study and other retrospective studies [9,12,50].